

# BIO DEUTSCHLAND

## European Business Development Conference

7 – 8 October 2014 | Dresden | Germany

Nils Debus

Dr Nils Peter Debus is Head Business Development for Boehringer Ingelheim's (Ingelheim/Germany) newly established Biosimilars Business Unit. He joined recently and is in charge of the Biosimilar Licensing and Business Development operations, which include strategy and portfolio support, patent licenses and pipeline optimization deals as well as commercialization and national roll-out licensing support.

Dr Debus has over 18 years of combined experience in Research and Business Development & Licensing within the healthcare industry. He has an extensive track record of searching, evaluating and executing external opportunities, including patent, product and technology licenses and strategic partnerships.

He joined Schering AG (Berlin/Germany) in 1996, which became later Bayer Healthcare, heading a research team in diagnostic imaging. In 2001 he joined the Business Development & Licensing team for almost ten years and spent during this time five years in the Bay Area being responsible for Business Development of Schering/Bayer's biotech subsidiary in Richmond/California. Three years ago Dr Debus accepted an invitation from Merz Pharmaceuticals, Frankfurt/Germany, to build up a global Licensing department and to head all worldwide Business Development & Licensing operations. Dr. Debus and his team executed several essential licensing deals for the company's portfolio change strategy.

Dr Debus studied Microbiology & Biochemistry and holds a Ph.D. in embryonic stem cell research from Humboldt University, Berlin/Germany. He received additional training in finance from Duke University Durham/NC.